Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) Shares Outstanding (Diluted Average) (2023 - 2025)

Immunome's Shares Outstanding (Diluted Average) history spans 3 years, with the latest figure at $87.4 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 48.96% year-over-year to $87.4 million; the TTM value through Dec 2025 reached $87.4 million, up 48.96%, while the annual FY2025 figure was $87.4 million, 48.96% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $87.4 million in Q4 2025 per IMNM's latest filing, up from $84.8 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $87.4 million in Q4 2025 to a low of $12.2 million in Q1 2023.
  • Average Shares Outstanding (Diluted Average) over 3 years is $51.4 million, with a median of $57.2 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Diluted Average): surged 393.39% in 2024, then soared 40.89% in 2025.
  • A 3-year view of Shares Outstanding (Diluted Average) shows it stood at $19.8 million in 2023, then soared by 195.51% to $58.6 million in 2024, then surged by 48.96% to $87.4 million in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Shares Outstanding (Diluted Average) are $87.4 million (Q4 2025), $84.8 million (Q3 2025), and $83.2 million (Q2 2025).